International Journal of Hematologic Oncology最新文献

{"title":"Living 20 years with multiple myeloma: an interview with Phil Falkowitz.","authors":"Phil Falkowitz","doi":"10.2217/ijh-2017-0016","DOIUrl":"https://doi.org/10.2217/ijh-2017-0016","url":null,"abstract":"<p><p><b>Phil Falkowitz speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Phil Falkowitz is 67 a year oldman who has lived with Multiple myeloma patient for 20 years. He has been married to his wife Barbara for 44 years and is currently raising a family of three. Phil graduated from Temple University (PA, USA) in 1972. He is one of the founders and charter members of the Philadelphia Multiple MyelomaNetworking Group which is now a fund raising entity of the I.M.F. Phil's interest inclassic cars has extended to his e-mail address thus resulting in G67vette@comcast.net (G for green).</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 2","pages":"39-42"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of antiretroviral therapy on clinical aspects of HIV-related lymphoma.","authors":"José-Tomás Navarro,&nbsp;Josep-Maria Ribera","doi":"10.2217/ijh-2017-0017","DOIUrl":"10.2217/ijh-2017-0017","url":null,"abstract":"“ The use of cART during chemotherapy is also controversial. However, our recommendation is to give cART concomitantly during chemotherapy, because antiretrovirals have been shown to decrease the risk of death and improve the prognosis of lymphoma ” Similar to the other immunosuppressed patients, individuals with HIV infection have an increased incidence of lymphomas. However, since 1996, the introduction of combination antiretroviral therapy (cART) has modified the natural history of some infections and malignancies, including lymphomas, which may affect HIV-infected individuals. The prognosis of both non-Hodgkin (NHL) and Hodgkin lymphoma (HL) has drastically improved in the cART era. The different chemotherapy regimens used in the general population are currently being administered to treat HIV-related NHL and HL with similar results to those obtained in the HIV-negative population. Several epidemiological studies have confirmed that the incidence of HIV-related lymphomas has decreased in the cART era along with other AIDS defining malignancies. On the other hand, the incidence of non-AIDS-defining cancers has increased [1 , 2] . However, lymphoma is still the most frequent malignancy among HIV-infected individuals and a frequent neoplastic cause of death among HIV-infected patients [2 , 3] . A better control of the HIV infection has been observed concomitant with the decrease in the incidence of lymphoma in the cART era. However, the changes in the incidence of HIV-related","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 2","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives.","authors":"Germana Castelli, Elvira Pelosi, Ugo Testa","doi":"10.2217/ijh-2016-0011","DOIUrl":"10.2217/ijh-2016-0011","url":null,"abstract":"<p><p>The rapid advancement of next-generation sequencing techniques and the identification of molecular driver events responsible for leukemia development are opening the door to new pharmacologic-targeted agents to tailor treatment of acute myeloid leukemia (AML) in individual patients. However, the use of targeted therapies in AML has met with only modest success. Molecular studies have identified AML subsets characterized by driver mutational events, such as <i>NPM1, FLT3-ITD</i> and <i>IDH1-2</i> mutations, and have provided preclinical evidence that the targeting of these mutant molecules could represent a valuable therapeutic strategy. Recent studies have provided the first pieces of evidence that FLT3 targeting in <i>FLT3</i>-mutant AMLs, IDH1/2 inhibition in <i>IDH</i>-mutant AMLs and targeting membrane molecules preferentially expressed on leukemic progenitor/stem cells, such as CD33 and CD123, represent a clinically valuable strategy.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 4","pages":"143-164"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172000/pdf/ijh-05-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are FLT3 inhibitors likely to improve <i>FLT3</i>-mutated acute myeloid leukemia in the foreseeable future?","authors":"Sabine Kayser,&nbsp;Mark J Levis","doi":"10.2217/ijh-2017-0001","DOIUrl":"https://doi.org/10.2217/ijh-2017-0001","url":null,"abstract":"9 ISSN 2045-1393 10.2217/IJH.12.32 © 2013 Future Medicine Ltd Int. J. Hematol. Oncol. (2013) 2(1), 9–11 Approximately one-quarter of acute myeloid leukemia (AML) cases are characterized by an internal tandem duplication (ITD) mutation in the FLT3 gene. Patients with FLT3-ITD AML carry an especially poor prognosis, with few patients surviving 5 years or longer [1,2]. Point mutations at the D835 locus on the FLT3 gene occur in approximately 8% of adult AML cases, although the prognostic value of de novo FLT3 D835 mutations remains a topic of debate [3–5]. A growing number of smallmolecule tyrosine kinase inhibitors (TKIs) are being developed as FLT3 inhibitors and used in clinical trials, primarily for the treatment of FLT3-ITD AML. Early failures of FLT3 inhibitors in clinical trials prompted speculation that the ITD may be a passenger mutation. However, in a Phase II study of the FLT3 inhibitor quizartinib, there was a population of FLT3-ITD AML patients who initially exhibited blast reduction to <5% but later relapsed. In this group of patients, the resistance to quizartinib was conferred by consistent point mutations at two specific amino acid residues in the FLT3 kinase domain, including the D835 residue [6]. This discovery of a reproducible, adaptive resistance mechanism to TKI treatment suggests that the FLT3-ITD represents a driver mutation in AML. A randomized trial of FLT3-mutated patients in f irst relapse receiving chemotherapy with or without the TKI lestaurtinib showed no overall survival benefit in the lestaurtinib arm [7]. Only 27% of patients receiving lestaurtinib achieved sustained, adequate FLT3 inhibition, due, at least in part, to the complex pharmacokinetics of this drug. Nevertheless, the study was encouraging insofar as there was a high degree of correlation between FLT3 inhibition and remission [7,8]. The newer FLT3 inhibitor quizartinib is particularly potent and selective, and these characteristics will likely help this drug overcome some of the challenges posed by earlier FLT3 inhibitors [9]. In the quizartinib Phase II study, the composite complete remission rate among relapsed FLT3-ITD AML patients aged ≥60 years was 54%, with an additional 17% of patients achieving a partial response [10].","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 4","pages":"123-126"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential role for all-<i>trans</i> retinoic acid in nonpromyelocytic acute myeloid leukemia.","authors":"Hayley S Ma,&nbsp;Tara M Robinson,&nbsp;Donald Small","doi":"10.2217/ijh-2016-0015","DOIUrl":"https://doi.org/10.2217/ijh-2016-0015","url":null,"abstract":"<p><p>All-<i>trans</i> retinoic acid (ATRA) has been very successful in the subtype of acute myelogenous leukemia known as acute promyelocytic leukemia due to targeted reactivation of retinoic acid signaling. There has been great interest in applying this form of differentiation therapy to other cancers, and numerous clinical trials have been initiated. However, ATRA as monotherapy has thus far shown little benefit in nonacute promyelocytic leukemia acute myelogenous leukemia. Here, we review the literature on the use of ATRA in combination with chemotherapy, epigenetic modifying agents and targeted therapy, highlighting specific patient populations where the addition of ATRA to existing therapies may provide benefit. Furthermore, we discuss the impact of recent whole genome sequencing efforts in leading the design of rational combinatorial approaches.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 4","pages":"133-142"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A look back at 2016 in <i>International Journal of Hematologic Oncology</i>.","authors":"Sebastian Dennis-Beron","doi":"10.2217/ijh-2017-0005","DOIUrl":"10.2217/ijh-2017-0005","url":null,"abstract":"","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 4","pages":"119-121"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia.","authors":"Xavier Thomas","doi":"10.2217/ijh-2017-0004","DOIUrl":"10.2217/ijh-2017-0004","url":null,"abstract":"of the","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 4","pages":"127-131"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco.","authors":"Francesco Lo-Coco","doi":"10.2217/ijh-2016-0013","DOIUrl":"https://doi.org/10.2217/ijh-2016-0013","url":null,"abstract":"<p><p><b>Francesco Lo-Coco speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Francesco Lo-Coco is currently a full professor of hematology and head of the Laboratory of Integrated Diagnosis of Oncohematologic Diseases at the Department of Biomedicine and Prevention of the University Tor Vergata of Roma. He obtained his MD degree from the University of Pisa in 1981, and his specialization in clinical and laboratory hematology is from the University La Sapienza of Rome in 1985. From 1992 to 1994, he has trained on molecular genetics of lymphomas at Columbia University, New York. His main scientific interest and research activities include genetic characterization, monitoring and treatment of hematologic tumors, particularly acute myeloid leukemia and acute promyelocytic leukemia (APL). He has published over 390 internationally peer-reviewed articles, mainly focused on molecular diagnosis and follow-up of leukemia as well as on treatment of APL. He chairs at present the APL subcommittee of the Italian National Cooperative Group, GIMEMA. He served as president of the Italian Society of Experimental Hematology, chairman of the Education Committee of the European Hematology Association, board member of the Italian Foundation for Cancer Research, member of the Committe on Health Research of the Italian Ministry of Health and member of the Editorial Board of the journals <i>Leukemia</i>, <i>Journal of Clinical Oncology</i> and <i>Haematologica</i>.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 3","pages":"101-104"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current first- and second-line treatment options in acute promyelocytic leukemia.","authors":"Fulvio Massaro, Matteo Molica, Massimo Breccia","doi":"10.2217/ijh-2016-0010","DOIUrl":"10.2217/ijh-2016-0010","url":null,"abstract":"<p><p>Outcome of acute promyelocytic leukemia (APL) has remarkably improved during the last 30 years, especially after the identification of <i>PML-RARA</i> oncogene as a key in the pathogenesis of APL and all-trans retinoic acid as therapeutic agent. Arsenic trioxide has been recently demonstrated to be the most effective single antileukemic agent and it has also showed synergistic action when combined with all-trans retinoic acid, decreasing relapse rate especially in low/intermediate-risk settings. Therapeutic advances led to complete remission rates of more than 90%, modifying disease history. In relapse setting, arsenic trioxide-based regimens showed efficacy for the achievement of second molecular complete remission. The most challenging issue in APL management remains the significant early deaths rate, nowadays the principal reason for treatment failure.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 3","pages":"105-118"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171971/pdf/ijh-05-105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying targetable genetic features in primary CNS lymphoma.","authors":"Agnieszka Korfel,&nbsp;Uwe Schlegel","doi":"10.2217/ijh-2016-0012","DOIUrl":"https://doi.org/10.2217/ijh-2016-0012","url":null,"abstract":"Department of Hematology & Oncology, Charite University Medicine Berlin, Berlin, Germany Department of Neurology, Ruhr-University Bochum, Krankenhaus Langendreer, Bochum, Germany *Author for correspondence: agnieszka.korfel@charite.de","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 3","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}